日产精品卡二卡三卡四卡乱码视频-欧美h在线观看-国产三级在线看-国内精品免费午夜又爽又色愉情-欧美狂躁少妇xxx-一区一区三区产品乱码-特级无码毛片免费视频播放▽-午夜福利伦伦电影理论片在线观看-2024av视频-日韩欧美视频在线播放-男男一级淫片免费播放-久久艳片www17ccom-污污网站在线播放-全球av在线-亚洲高清免费视频-超碰不卡-99精品热视频-国产又大又粗又爽-亚洲偷自拍国综合色帝国-日韩av网页

Welcome to Linuo Group!HomeBusiness License
  • CN

  • WeChat

  • Mobile Site

  • Search

力諾資訊

Keyuan Pharma Wins 2025 Forbes China Industry Development Innovative Brand Award

2025.04.02

Shandong Keyuan Pharmaceutical Co., Ltd. has been awarded the 2025 Forbes China Industry Development Innovative Brand Award at the 2025 Forbes China Industry Development Pioneers Selection held in Shanghai on March 22nd, in recognition of its exceptional innovation capabilities and significant industry influence.

The accolade not only represents high recognition of Keyuan Pharma's years of dedicated efforts in the field of chemical APIs and preparations but also stands as a powerful testament to its leapfrog development driven by innovation amid the adjustments in the global industrial landscape.

Jointly initiated by Frost & Sullivan, a world-renowned growth consulting firm, and Forbes China Group, the 2025 Forbes China Industry Development Pioneers Selection aims to identify outstanding enterprises and individuals in key sectors such as new energy, AI technology, mass consumption, and biomedicine that are driving industry transformation with an innovative spirit. Keyuan Pharma's success in standing out this time underscores its prominent position in the chemical drug sector.

Founded in 2004, Keyuan Pharmaceutical has focused on the R&D, production, and sales of chemical APIs and preparations. It has established three core product lines: anti-diabetic, cardiovascular, and anesthetic drugs, and ranks as a backbone enterprise in the field of chemical synthetic drugs in Shandong Province.

Innovation is the core driving force behind Keyuan Pharma's development. The company has continuously increased its R&D investment, actively explored cutting-edge technologies, and improved its innovation system. Recently, Keyuan Pharma obtained the utility model patent authorization for "a raw material preliminary processing and drying device for metformin hydrochloride processing," marking the fourth patent authorization it has received this year. A series of patent achievements have provided solid support for improving product quality, enhancing production efficiency, and controlling costs, helping the company gain an edge in the fierce market competition.